elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q47610511-28D7D843-822E-4C9A-860F-AC436A5BA016
Q47610511-28D7D843-822E-4C9A-860F-AC436A5BA016
BestRank
Statement
http://www.wikidata.org/entity/statement/Q47610511-28D7D843-822E-4C9A-860F-AC436A5BA016
Targeting Human-Cytomegalovirus-Infected Cells by Redirecting T Cells Using an Anti-CD3/Anti-Glycoprotein B Bispecific Antibody.
P2860
Q47610511-28D7D843-822E-4C9A-860F-AC436A5BA016
BestRank
Statement
http://www.wikidata.org/entity/statement/Q47610511-28D7D843-822E-4C9A-860F-AC436A5BA016
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
215eb5e8ed2478437209ae1f9ecff8326a015ccf
P2860
FDA Approval: Blinatumomab.